[1]包文平,杨 帆,徐佳栋,等.膀胱癌患者血清miR-144、miR-618和CK19水平变化及检测意义[J].陕西医学杂志,2026,(5):639-643.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.011]
　BAO Wenping,YANG Fan,XU Jiadong,et al.Changes of serum miR-144,miR-618 and CK19 levels in patients with bladder cancer and their detection significance[J].,2026,(5):639-643.[doi:DOI:10.3969/j.issn.1000-7377.2026.05.011]
点击复制

膀胱癌患者血清miR-144、miR-618和CK19水平变化及检测意义

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2026年5期
页码:
639-643
栏目:
临床研究
出版日期:
2026-05-05

文章信息/Info

Title:
Changes of serum miR-144,miR-618 and CK19 levels in patients with bladder cancer and their detection significance
作者:
包文平; 杨 帆; 徐佳栋; 刘先艮
（南通大学附属南通第三医院泌尿外科，江苏 南通 226000）
Author(s):
BAO Wenping; YANG Fan; XU Jiadong; LIU Xiangen
(Department of Urology,Nantong Third Hospital Affiliated to Nantong University,Nantong 226000,China)
关键词:
膀胱癌; 微小RNA-144; 微小RNA-618; 细胞角蛋白19; 临床病理特征; 诊断价值
Keywords:
Bladder cancer; miR-144; miR-618; CK19; Clinicopathological features; Diagnostic value
分类号:
R737.14
DOI:
DOI:10.3969/j.issn.1000-7377.2026.05.011
文献标志码:
A
摘要:
目的：探讨膀胱癌患者血清微小RNA-144（miR-144）、miR-618和细胞角蛋白19（CK19）水平变化及检测意义。方法：选取86例膀胱癌患者为膀胱癌组，同期86例泌尿系统良性疾病患者（膀胱炎、前列腺增生、尿路结石）为良性疾病组。采用RT-qPCR检测两组血清miR-144、miR-618水平，ELISA法测定血清CK19浓度，分析三者水平与膀胱癌患者临床病理特征的关系，Pearson法分析血清miR-144、miR-618及CK19水平的相关性，受试者工作特征（ROC）曲线评估各指标及联合检测对膀胱癌与泌尿系统良性疾病的鉴别诊断价值。结果：膀胱癌组血清miR-144水平低于良性疾病组，血清miR-618、CK19水平高于良性疾病组（均P<0.05）。血清miR-144在肿瘤分期T2-T4期、病理分级G3级、有淋巴结转移、肿瘤直径≥3 cm的膀胱癌患者中表达水平低于肿瘤分期Ta-T1期、病理分级G1-G2级、无淋巴结转移、肿瘤直径<3 cm的患者（均P<0.05）。血清miR-618与CK19在肿瘤分期T2-T4期、病理分级G3级、有淋巴结转移、肿瘤直径≥3 cm的膀胱癌患者中表达水平高于肿瘤分期Ta-T1期、病理分级G1-G2级、无淋巴结转移、肿瘤直径<3 cm的患者（均P<0.05）。膀胱癌患者血清miR-144与miR-618、CK19水平呈负相关，血清miR-618与CK19水平呈正相关（均P<0.05）。血清miR-144、miR-618、CK19单独诊断膀胱癌的曲线下面积（AUC）分别为0.753、0.778、0.765，三者联合诊断的AUC为0.897，高于各指标单独诊断的AUC（均P<0.05）。结论：膀胱癌患者血清miR-144呈低表达，miR-618与CK19呈高表达，三者与患者临床病理特征有关，联合检测可提高膀胱癌与泌尿系统良性疾病的鉴别诊断效能。
Abstract:
Objective:To explore the changes of serum microRNA-144 (miR-144),miR-618 and cytokeratin 19 (CK19) levels in patients with bladder cancer and their detection significance.Methods：A total of 86 patients with bladder cancer were enrolled as the bladder cancer group,and 86 patients with benign urinary system diseases (cystitis,benign prostatic hyperplasia,urinary calculi) were selected as the benign disease group.RT-qPCR was used to detect serum levels of miR-144 and miR-618 in both groups,and ELISA was adopted to determine serum CK19 concentration.The relationship between the three indicators and the clinicopathological features of bladder cancer patients was analyzed.Pearson correlation analysis was used to explore the correlation among serum miR-144,miR-618 and CK19 levels.ROC curve was employed to evaluate the differential diagnostic value of each indicator alone and in combination for bladder cancer and benign urinary system diseases.Results:Serum miR-144 level in the bladder cancer group was lower than that in the benign disease group,while serum miR-618 and CK19 levels were higher than those in the benign disease group (all P<0.05).Serum miR-144 expression level was lower in bladder cancer patients with tumor stage T2-T4,pathological grade G3,lymph node metastasis and tumor diameter ≥3 cm than in those with tumor stage Ta-T1,pathological grade G1-G2,no lymph node metastasis and tumor diameter <3 cm (all P<0.05).Serum miR-618 and CK19 expression levels were higher in bladder cancer patients with tumor stage T2-T4,pathological grade G3,lymph node metastasis and tumor diameter ≥3 cm than in those with tumor stage Ta-T1,pathological grade G1-G2,no lymph node metastasis and tumor diameter <3 cm (all P<0.05).In bladder cancer patients,serum miR-144 level was negatively correlated with miR-618 and CK19 levels,and serum miR-618 level was positively correlated with CK19 level (all P<0.05).The AUC of serum miR-144,miR-618 and CK19 alone for diagnosing bladder cancer was 0.753,0.778 and 0.765,respectively.The AUC of the combined detection of the three indicators was 0.897,which was higher than that of each indicator alone (all P<0.05).Conclusion:Serum miR-144 is lowly expressed,while miR-618 and CK19 are highly expressed in patients with bladder cancer.The three indicators are related to the clinicopathological features of patients,and combined detection can improve the differential diagnostic efficacy between bladder cancer and benign urinary system diseases.

参考文献/References:

[1]梁博,何跃,刘泓键,等.膀胱癌组织中miR-144、肺癌转移相关转录本1及睾丸蛋白聚糖表达及其诊断价值[J].临床外科杂志,2023,31(5):440-443.
[2]吴德柱,李清林,彭娜,等.膀胱癌患者血清miR-21、miR-119a表达量与肿瘤恶性增殖及侵袭的相关性分析[J].转化医学杂志,2022,11(1):9-13.
[3]ELSALEM L,ALEIKISH A A,AL-AZZAM N,et al.Serum xanthine oxidoreductase and oxidative stress are associated with bladder cancer:A case-control study from Jordan[J].J Appl Biomed,2025,23(3):107-116.
[4]GE Z,LIN S,LU C,et al.Panel containing three serum microRNAs:A promising biomarker for early detection of bladder cancer[J].Front Oncol,2024,14:1470457.
[5]闫三华,李光耀,刘超.吲哚菁绿荧光标记低pH插入肽、细胞角蛋白19、血管内皮生长因子C联合尿液脱落细胞学检查在膀胱癌早期诊断中应用价值[J].临床军医杂志,2024,52(12):1282-1284.
[6]牛莹莹,田河,李悦,等.尿液中期因子和细胞角蛋白19在膀胱癌诊断中的应用价值[J].现代肿瘤医学,2025,33(10):1712-1718.
[7]邱忠凯,刘俊龙,丁全明,等.膀胱癌患者血清中肿瘤异常蛋白和细胞角蛋白19的表达及其临床意义[J].中国医科大学学报,2023,52(7):628-632.
[8]杨新选,任航.膀胱癌患者血清miR-143、miR-144和miR-145水平变化及临床意义[J].海南医学,2021,32(21):2725-2729.
[9]JIANG X,QU A,ZHANG S,et al.RNA-seq profiling identified a three-lncRNA panel in serum as potential biomarker for muscle-invasive bladder cancer[J].Front Oncol,2024,14:1451009.
[10]ZHAO L,TIAN G,WANG X,et al.Clinical significance of a new early diagnostic model for bladder cancer based on genome-wide microarray profiling of serum exosomal lncRNAs[J].Int Urol Nephrol,2025,57(6):1771-1783.
[11]陶涛,任承德,陈国俊,等.miR-144-3p通过调控ABCG2信号通路对膀胱癌细胞增殖、凋亡及迁移作用的影响[J].中国老年学杂志,2022,42(14):3590-3593.
[12]HUANG Z,ZHANG W,HUANG K,et al.Determination of serum vitamin D in patients with renal,bladder,and prostate cancer by ultra-performance liquid chromatography-tandem mass spectrometry[J].Neoplasma,2024,71(5):463-472.
[13]王丹,张前进,吴娟.膀胱癌患者血清miR-124、miR-320a水平与临床病理特征及生存预后的关系[J].国际检验医学杂志,2024,45(5):608-613.
[14]WANG T,ZHANG X,ZHANG G M.Commentary:Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis[J].Front Oncol,2024,14:1417921.
[15]李绪鲲,刘星,唐义权.膀胱癌患者血清CK-19、CYFRA21-1的表达及其临床意义[J].中国现代医学杂志,2021,31(22):17-21.
[16]IKUMA S,AKATSUKA J,ENDO Y,et al.2004P The combination of high levels of serum cytokeratin fragment 21-1 and Ⅵ-RADS≧4 has diagnostic and prognostic value in high-stage bladder cancer[J].Ann Oncol,2024,35(S2):S1158.
[17]石小玲,顾叶飞,蔡芸.膀胱癌组织和血清miR-200b甲基化状态与EMT及临床病理特征的相关性研究[J].东南大学学报(医学版),2022,41(1):95-101.
[18]FATTAHI M J,SEDAGHAT F,HAGHSHENAS R,et al.Two metabolic enzymes,LDH and FASN,serum levels in bladder cancer patients[J].Caspian J Intern Med,2024,15(4):636-643.
[19]陈卫华,龚化,曾皓.彩色多普勒超声联合血清miR-128-3p和DJ-1测定对膀胱癌及其临床分期的诊断价值研究[J].中国医学装备,2023,20(12):82-86.
[20]谷士海,傅文生,邢化志.miR-618在非小细胞肺癌中的表达及临床意义[J].临床肺科杂志,2020,25(4):583-587,632.
[21]谢振华,祁洪刚,张曙伟,等.血清CK19和AFP等七项肿瘤标志物联合诊断膀胱癌的研究[J].中国现代医生,2017,55(32):23-26,封3.
[22]胡姣.Siglec15促进膀胱癌非炎性肿瘤微环境形成并介导免疫治疗耐药[D].长沙:中南大学,2022.
[23]吴万文,吕蔡,刘振湘,等.血清异常糖链糖蛋白联合尿细胞角蛋白-19检测对膀胱癌早期诊断的价值[J].天津医药,2019,47(10):1085-1088.
[24]王晓甫,张云翔,张胜威,等.膀胱肿瘤抗原、尿核基质蛋白22、细胞角蛋白-19对膀胱癌的诊断价值分析[J].癌症进展,2024,22(15):1667-1670.
[25]郑元振.血清血管内皮

相似文献/References:

[1]林 晨,刘湘鄂,吴天玉 ,等.尾型同源盒转录因子2和同源框蛋白A9在膀胱癌组织中的表达及临床意义*[J].陕西医学杂志,2019,(8):972.
　LIN Chen,LIU Xiange,WU Tianyu,et al.Expressions of CDX2 and HOXA9 in bladder cancer and their relationships with prognosis[J].,2019,(5):972.
[2]赵刚刚,张鸿毅,肖克兵,等.自然杀伤细胞2组成员A、程序性死亡因子配体1表达检测对PD-L1阻断免疫治疗肌层浸润性膀胱癌反应性的预测价值[J].陕西医学杂志,2024,(2):252.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.023]
　ZHAO Ganggang,ZHANG Hongyi,XIAO Kebing,et al.Value of NKG2A and PD-L1 expression in predicting responsiveness of PD-L1 blocking immunotherapy for myometrial invasive bladder cancer[J].,2024,(5):252.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.023]
[3]徐 律,张 炜,胡 志,等.长链非编码RNA LINC00106调控微小RNA-19b对膀胱癌细胞增殖和迁移的影响[J].陕西医学杂志,2025,54(5):579.[doi:DOI:10.3969/j.issn.1000-7377.2025.05.001]
　XU Lv,ZHANG Wei,HU Zhi,et al.Effects of long non-coding RNA LINC00106 on the proliferation and migration of bladder cancer cells via regulation of miR-19b[J].,2025,54(5):579.[doi:DOI:10.3969/j.issn.1000-7377.2025.05.001]

备注/Memo

备注/Memo:
江苏省自然科学基金资助项目（2023FLR-1062）；南通大学临床医学专项科研基金资助项目（2023JY029）
更新日期/Last Update: 2026-05-05